期刊文献+

益筋方对实验性重症肌无力小鼠T细胞及IL-2的影响 被引量:2

Effect of Yi Jin Prescription on T Cells and IL-2 in Experimental Myasthenia Gravis Mice
原文传递
导出
摘要 目的探讨温肾活血、益气升清的益筋方对实验性自身免疫性重症肌无力(MG)小鼠的治疗机理。方法采用重症肌无力患者的血清被动免疫小鼠,建立实验性自身免疫性重症肌无力模型。分组后分别给予益筋方、强的松灌胃21d,处死动物、采血。利用流式细胞技术,以T细胞及其亚群、IL-2为指标,观察益筋方、强的松对实验性重症肌无力小鼠细胞免疫和细胞因子的影响。结果强的松、益筋方均能升高CD3+,降低CD4+/CD8+比值;降低IL-2。结论益筋方能通过影响T细胞及其亚群、细胞因子,调控细胞免疫和体液免疫,起到治疗重症肌无力的作用。 Objective To study the mechanism of Yi Jin Prescription treating the mice with myasthenia gravis(MG) caused by the disease of autoimmunity. Methods Experimental autoimmune myasthenis gravis mouse model was established with C57BL/6 mice immunized with plasma of myasthenia gravis. Mice were treated with prednisone and Yi Jin Prescription by intragastric administration and killed after 21 days. By using the flow cytometry, the effects of Yi Jin Prescription and prednisone on the T lymphocyte,T lymphocyte subgroups and IL-2 of the experimental myasthenia gravis mice were observed respectively. Results Both prednisone and Yi Jin Prescription increased the ratio of CD3^+ T lymphocyte, and decreased the ratio of CD4^+/CD8^+ and the level of IL-2. Conclusion Yi Jin Prescription can regulate cytoimmunity and humoral immunity by influencing T lymphocyte and its subgroup and IL-2.
出处 《中华全科医学》 2009年第3期226-228,共3页 Chinese Journal of General Practice
基金 山东省中医药科技发展计划(2005-078)
关键词 重症肌无力 益筋方 T细胞 IL-2 Myasthenia gravis Yi Jin Prescription T lymphocyte IL-2
  • 相关文献

参考文献6

二级参考文献35

  • 1吕祥龙,张晓雷.甲基强的松龙冲击治疗重症肌无力Ⅱa型出现呼吸肌麻痹(附8例报告)[J].淮海医药,2004,22(6):526-527. 被引量:4
  • 2常文利.27例重症肌无力危象抢救分析[J].实用神经疾病杂志,2005,8(3):52-53. 被引量:4
  • 3Hoedernaekers AC, Verschuuren JJ, Spaans F, et al. Age related susceptibility to experimental autoimmune myasthenia gravis: immunological and electrophysiological aspects[J]. Muscle Nerve, 1997, 20(9): 1091-1101.
  • 4Lee KW, Lee SH, Kim HJ, et al. Experimental autoimmune myasthenia gravis and CD5+ B-lymphocyte expression[J]. J Korean Med Sci, 1999, 14(1):75-79.
  • 5Wang HB, Shi FD, Li H, et al. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis[J]. J Immunol, 2001, 166(10): 6430-6436.
  • 6Paas-Rozner M, Sela M, Mozes E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes[J]. Proc Natl Acad Sci USA, 2001, 98(22): 12642-12647.
  • 7Scelsa S, Frost M, Valderrama R, et al. Prevention and treatment of experimental autoimmune myasthenia gravis with anti-rabbit thymocyte serum and gammaglobulin in rabbits[J]. Pathobiology, 1995, 63(3): 168-174.
  • 8Paas-Rozner M, Dayan M, Paas Y, et al. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice[J]. Proc Natl Acad Sci USA, 2000, 97(5): 2168-2173.
  • 9Oshima M, Pachner AR, Atassi MZ. Molprofile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor[J]. Immunology, 1994, 31(11): 833-843.
  • 10Wang ZY, Karachunski PI, Howard JF Jr. et al. Myasthenia in SCID mice grafted with myasthenia patient lymphocytes[J]. Neurology, 1999, 52(3): 484-497.

共引文献29

同被引文献45

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部